



Version of attached ﬁle:
Published Version
Peer-review status of attached ﬁle:
Peer-reviewed
Citation for published item:
McKenzie, L. K. and Sazanovich, I. V. and Baggaley, E. and Bonneau, M. and Guerchais, V. and Williams, J.
A. G. and Weinstein, J. A. and Bryant, H. E. (2017) 'Metal complexes for two-photon photodynamic therapy :
a cyclometallated iridium complex induces two-photon photosensitization of cancer cells under near-IR light.',
Chemistry : a European journal., 23 (2). pp. 234-238.
Further information on publisher's website:
https://doi.org/10.1002/chem.201604792
Publisher's copyright statement:
c© 2016 The Authors. Published by Wiley-VCH Verlag GmbH Co. KGaA. This is an open access article under the
terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium,
provided the original work is properly cited.
Additional information:
Use policy
The full-text may be used and/or reproduced, and given to third parties in any format or medium, without prior permission or charge, for
personal research or study, educational, or not-for-proﬁt purposes provided that:
• a full bibliographic reference is made to the original source
• a link is made to the metadata record in DRO
• the full-text is not changed in any way
The full-text must not be sold in any format or medium without the formal permission of the copyright holders.
Please consult the full DRO policy for further details.
Durham University Library, Stockton Road, Durham DH1 3LY, United Kingdom
Tel : +44 (0)191 334 3042 | Fax : +44 (0)191 334 2971
http://dro.dur.ac.uk
& Photoactive Complexes
Metal Complexes for Two-Photon Photodynamic Therapy: A
Cyclometallated Iridium Complex Induces Two-Photon
Photosensitization of Cancer Cells under Near-IR Light
Luke K. McKenzie,[a, b] Igor V. Sazanovich,[a, b, e] Elizabeth Baggaley,[b] Micka[le Bonneau,[c, d]
V8ronique Guerchais,[d] J. A. Gareth Williams,[c] Julia A. Weinstein,*[b] and Helen E. Bryant*[a]
Chem. Eur. J. 2017, 23, 234 – 238 T 2017 The Authors. Published by Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim234
CommunicationDOI: 10.1002/chem.201604792
Abstract: Photodynamic therapy (PDT) uses photosensitiz-
ers (PS) which only become cytotoxic upon light-irradia-
tion. Transition-metal complexes are highly promising PS
due to long excited-state lifetimes, and high photo-stabili-
ties. However, these complexes usually absorb higher-
energy UV/Vis light, whereas the optimal tissue transpar-
ency is in the lower-energy NIR region. Two-photon exci-
tation (TPE) can overcome this dichotomy, with simultane-
ous absorption of two lower-energy NIR-photons populat-
ing the same PS-active excited state as one higher-energy
photon. We introduce two low-molecular weight, long-
lived and photo-stable iridium complexes of the
[Ir(N^C)2(N^N)]
+ family with high TP-absorption, which lo-
calise to mitochondria and lysosomal structures in live
cells. The compounds are efficient PS under 1-photon irra-
diation (405 nm) resulting in apoptotic cell death in di-
verse cancer cell lines at low light doses (3.6 Jcm@2), low
concentrations, and photo-indexes greater than 555. Re-
markably 1 also displays high PS activity killing cancer
cells under NIR two-photon excitation (760 nm), which
along with its photo-stability indicates potential future
clinical application.
Photodynamic therapy (PDT) is a light-activated treatment of-
fering reduced side effects compared to traditional therapy.[1]
The PDT agent, a photosensitizer (PS), is only activated upon
targeted irradiation by light of a PS-specific wavelength which
promotes the PS to its excited, high-energy state (*PS).
In oxygen-dependent PDT, cellular oxygen and *PS interac-
tions allow excited-state energy transfer, regenerating the
ground state of the PS and producing reactive oxygen species
(ROS) including singlet oxygen (1O2), with subsequent reactions
with the intracellular components leading to cell death. Target-
ed intracellular localisation of the PS is important for maximum
effect with organelles situated nearest to *PS being the most
affected.[2]
The photo-physical properties of many transition metal com-
plexes make them ideal PS candidates. Their key advantage
over organic molecules is the heavy atom effect which favours
fast singlet to triplet intersystem crossing (ISC). The longer life-
times, which result from ISC, lead to high yields of 1O2 and/or
other ROS. The ease of chemical modification and photo-stabil-
ity adds to the appeal of these complexes. Accordingly, an in-
creasing number of transition metal complexes have been in-
vestigated for use in PDT including those of PtIV, PtII, RuII, ReI,[3]
and IrIII.[4]
One limitation to the clinical use of metal complexes investi-
gated for PDT has been their absorption of light in the UV/Vis
region, as the optimal tissue penetration window is 700–
900 nm. Two-photon excitation (TPE), or two-photon PDT (TP-
PDT) can overcome this barrier. Compounds with high PDT ac-
tivity under one-photon excitation at a particular wavelength
in the UV/Vis region, should theoretically show PDT-activity
under TPE in the low-energy NIR region, with the simultaneous
advantages of the range of relative tissue transparency, in-
creased potential depth of tissue penetration, and increased
spatial targeting.[5] TP-PDT requires high two-photon absorp-
tion cross-section and exceptional photo-stability ruling out
current clinical photosensitizers. A number transition metal
complexes[3c, 6] have been developed as two-photon agents,
some of which have been shown to induce TPE cell killing in
vitro using cell cultures.[3c, 6a, 7]
We present herein two low-molecular-weight, mitochondrial
and lysosomal targeting, iridium complexes which display
good PS activity under one-photon excitation in a number of
cancer cell lines. Remarkably, one of the complexes is also an
efficient PS inducing cell death under TPE, and thus displays
highly promising results for TP-PDT.
The new iridium complexes 1 and 2 (Figure 1) are members
of the [Ir(N^C)2(N^N)]
+ family and closely related to the com-
plex [Ir(ppy)2(pybzH)]
+ .[8] 1 and 2 feature bisbenzimidazole and
its N,N-dimethylated derivative, respectively, as the N^N ligand
(Figure 1). The complexes were prepared as their hexafluoro-
phosphate salts from the chloro-bridged dimer [Ir(ppy)2(m-Cl)]2,
by reaction with 2,2’-bisbenzimidazole or 1,1’-dimethyl-2,2’-bis-
benzimidazole (for 1 and 2, respectively), (Supporting Informa-
tion, Figures S3–S5). The absorption spectra of 1 and 2 show
moderately intense absorption bands in the visible region due
to MLCT transitions (Supporting Information, Figure S2). The
Figure 1. Complexes 1 and 2.
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emission quantum yields are 0.33 and 0.24, respectively, Emis-
sion lifetimes of the order of a microsecond indicate the triplet
nature of the emissive state. Importantly, the complexes phos-
phoresce intensely also under NIR TPE; and 1 has an apprecia-
ble two-photon cross-section of 112 GM at 760 nm (Supporting
Information, Figure S2).
The TPE phosphorescence imaging of 1 and 2 demonstrate
cellular uptake (Supporting Information, Figure S3) with cyto-
plasmic localisation, similar to that of the previously reported
biscyclometallated iridium complexes.[4b,d] Co-localisation ex-
periments with organelle-specific fluorescent dyes demonstrate
mitochondrial and lysosomal localisation. Within 4 h of expo-
sure, mitochondrial localisation is observed with a Pearson’s
correlation coefficient r=0.547 (Figure 2A and Supporting In-
formation, Figure S4). Additionally, from 2 h increasing lysoso-
mal staining occurs. By 24 h the lysosomal localisation of 1 be-
comes dominant with Pearson’s correlation coefficients of r=
0.387 compared to 0.19 for the mitochondrial staining (Fig-
ure 2B and Supporting Information, Figure S4).
Cellular uptake was not observed at 4 8C indicating that 1 is
actively taken up rather than entering cells by passive diffusion
(Supporting Information, Figure S5). A number of cellular
uptake pathways were inhibited to determine the uptake
route (Supporting Information, Figure S5). Only valinomycin,
which is known to cause an increase in the membrane poten-
tial of cells, had an inhibitory effect on the uptake of 1 (Sup-
porting Information, Figure S5). Thus uptake of 1 appears to
largely occur via a cell membrane potential-dependent path-
way which is consistent with it being a singly-charged cation.
Clonogenic survival assays in the cervical cancer cell line,
HeLa demonstrate that 1 and 2 show high light cytotoxicity
giving LD50 values of 0.3 and 0.5 mm respectively (405 nm,
3.6 Jcm@2 ; Figure 3 and Supporting Information, Figure S6).
Complex 1 shows low dark cytotoxicity, with an LD50 of
>100 mm, whereas 2 shows a much higher dark cytotoxicity,
LD50=6.2 mm. Comparative PDT activity of a compound can be
estimated by the value of the photo-toxicity index (PI), PI=
LD50
dark/LD50
light. The lowest estimated PI for 1 in HeLa cells is
>333, but only 12.4 for 2 due to its high dark cytotoxicity,
hence 2 was not investigated further. The increased dark tox-
icity of 2 compared to 1 is likely due to the presence of N@Me
groups, which would rule out H-bonding and profoundly
affect intermolecular interactions within the cells. 1 also shows
photosensitizing effects in a number of cancer cell lines (Sup-
porting Information, Figure S6), demonstrating the potential
broad applicability of 1 for PDT.
To evaluate the importance of oxygen in cell killing by 1 and
2, the yield of singlet oxygen generation was measured. In air-
equilibrated dichloromethane, high F(1O2) of 42% and 40%
for 1 and 2 respectively were determined directly from the
emission of the 1Dg state of O2 in the NIR (lem 1275 nm) under
355 nm irradiation, demonstrating the ability of the complex
Figure 2. Subcellular localisation of 1. U2OS cells following 4 or 24 hour in-
cubation with 1 (green), co-localised with: A) Mitotracker orange (red), or
B) Lysotracker (red). Zoomed sections are shown as insets. Scale
bars=20 mm.
Figure 3. One-photon-induced PS activities of complexes 1 and 2. A) Survival
of HeLa cells pre-incubated for 2 or 24 h with complexes 1 or 2 + /@ light.
B) Anexin V staining in HeLa cells. C) Survival of bladder (EJ), osteosarcoma
(U2OS), melanoma (A375) and colorectal (HCT116) cancer cells 1 + /@ light
treatment.
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to generate singlet oxygen. In a cellular environment, singlet
oxygen immediately reacts with the surroundings, from this
point of view, the detection of ROS in cells is an important
measurement as it confirms an increase of cellular ROS concen-
tration in the presence of the complex. Here, an approximate
8-fold increase in ROS was detected in cells treated with 1 and
light (405 nm) compared to cells treated with light alone (Sup-
porting Information, Figure S7). Efficient intracellular ROS pro-
duction and 1O2 production in solution are suggestive of an
oxygen dependant mechanism of cell killing.
The mechanism of cell death was determined to be apopto-
sis (Supporting Information, Figure S6). It is proposed that
apoptotic cell death after light treatment is associated with lo-
calisation of photosensitizers to both the mitochondria and
the lysosomes.[9] Here, similar photosensitizing efficacy is seen
when the cells were exposed to light following a 2 h incuba-
tion—after which mainly mitochondrial localisation is seen, or
a 24 h incubation—after which mainly lysosomal localisation is
seen (Figure 3). We therefore suggest that light induced cell
death by 1 may be due to disruption of one or both of these
organelles, which can trigger apoptotic cell death.
The photosensitizing activity of 1 under TPE with 760 nm
light was investigated in HeLa cells (Figure 4). The resulting
images show apoptosis (green) and cell death (red) induced by
TPE photosensitization. The 1-exposed cells within the irradiat-
ed square clearly show apoptosis/cell death, whereas the sur-
rounding non-irradiated cells do not. Little to no killing of cells
is seen in the absence of 1 with light power as high as 25 mW
which under these conditions relates to a dose of 2720 Jcm@2,
this is the lower end of light doses reported to date for two-
photon photosensitizers.[7a–c] This result therefore demonstrates
the potential of 1 as a specific two-photon-activated PS at low
concentrations and at doses of light that, alone, are not harm-
ful to cells.
In summary, we introduce two novel small-molecule IrIII com-
plexes, which are cell-permeable, easy to synthesize, possess
long-lived triplet excited states, high linear absorption cross
sections in the visible range, and high two-photon absorption
cross sections in the NIR range of the spectrum. 1 has low dark
toxicity and is rapidly and actively taken up into a diverse
range of cancer cell types, in which localisation is primarily in
the mitochondria and lysosomes. High PS activity of 1 has
been demonstrated in a number of cancer cell lines under
one-photon excitation with 405 nm light, with an impressive PI
index of >333 and up to 555 depending on cell line (lower
limit estimate). Remarkably, 1 is also active in photosensitizing
cell death by apoptosis under NIR TPE (760 nm), at low con-
centrations and light doses.
Overall, the results demonstrate the exciting potential of
1 as a future two-photon PDT agent, and illuminate the poten-
tial of IrIII complexes as TP-PDT agents.
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